Eric got his PhD in 2004 from the University of Alberta studying the molecular mechanisms of bile acid metabolism. He then went to the University of Cincinnati for a PostDoc studying the mechanisms of macronutrient absorption in the gut and its role in disease. In 2008 Eric joined the newly formed Ardelyx, a biotech company devoted to discovering small molecule drugs that are non-absorbed and affect human health from the gut. Eric was lead in vivo pharmacologist for 2 programs that went to the clinic. Eric was then recruited in 2014 to Relypsa to lead in vivo pharmacology in drug discovery for the research group. He joined Recursion with a commitment to advance the drug discovery pipeline and help achieve the company’s potential for an audacious portfolio. Eric has 3 patents and16 peer-reviewed research publications throughout his career. He enjoys cooking, history, and running.
Are you Recursion ready?
Join our passionate, innovative team—and help us realize our goal of 100 treatments by 2025.